{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:38:48Z","timestamp":1782409128779,"version":"3.54.5"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Increased levels of inflammatory cytokines in multiple myeloma (MM) patients and the role of inflammation in disease pathogenesis, have recently been considered. The aim of this study was to quantitatively evaluation of fecal calprotectin (CP) as a non-invasive biomarker for the evaluation of inflammation in patients with multiple myeloma. This study is a hospital-based case control study. MM patients referred to patients referred to medical centers of Tehran province, Iran, were identified and classified into two groups of new MM patients (n = 40) and patients undergoing treatment (n = 28). Healthy individuals were included in the study as healthy control (n = 25). Morning stool samples were collected and CP was extracted immediately. After collecting the samples, CP was measured according to ELISA method and was determined in \u03bcg\/g of feces. Values \u200b\u200babove 50 \u03bcg\/g of feces are positive and indicate inflammation. The results revealed that there is a significant difference between groups in terms if CP mean (p = 0.001). The mean of CP among new cases, under treatment and control groups were 301.3 (SD: 141.0), 165.1 (SD: 153.9) and 36.9 (SD: 13.5), respectively. Then the groups were compared in pairs, the results showed that the new case group was significantly different from the under-treatment group (p = 0.001), and also the control group showed a significant difference with the new case group (p = 0.001) and the under-treatment group (p = 0.001) that the amount of CP in the control group was significantly lower than the other two groups. In addition, the results of the study showed a significant correlation between age and plasma cells with CP value, so that with increasing age and plasma cells, CP value also showed a significant increase. The results indicate that quantitative evaluation of CP as a non-invasive laboratory biomarker has a high potential as a clinical marker in patients with multiple myeloma and inflammation should considered as a hallmark of cancer. Further diagnostic studies are recommended.<\/jats:p>","DOI":"10.1371\/journal.pone.0282841","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T17:47:58Z","timestamp":1678988878000},"page":"e0282841","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Calprotectin as new potential clinical marker for multiple myeloma"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-1903","authenticated-orcid":true,"given":"Parisa","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Abroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Kaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Masoudifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homayoun Sarough","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"5","key":"pone.0282841.ref001","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"AJ Cowan","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"pone.0282841.ref002","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jama.2021.25306","article-title":"What Is Multiple Myeloma?","volume":"327","author":"J Silberstein","year":"2022","journal-title":"JAMA"},{"key":"pone.0282841.ref003","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fonc.2020.00189","article-title":"Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?","volume":"10","author":"N Bolli","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0282841.ref004","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","article-title":"Myeloma today: Disease definitions and treatment advances","volume":"91","author":"SV Rajkumar","year":"2016","journal-title":"American journal of hematology"},{"key":"pone.0282841.ref005","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma","volume":"9","author":"D Harmer","year":"2018","journal-title":"Frontiers in endocrinology"},{"key":"pone.0282841.ref006","doi-asserted-by":"crossref","first-page":"155271","DOI":"10.1016\/j.cyto.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"S Jasrotia","year":"2020","journal-title":"Cytokine"},{"key":"pone.0282841.ref007","doi-asserted-by":"crossref","first-page":"542363","DOI":"10.1155\/2013\/542363","article-title":"The Role of Calprotectin in Pediatric Disease","volume":"2013","author":"G Vaos","year":"2013","journal-title":"BioMed Research International"},{"issue":"2","key":"pone.0282841.ref008","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-3083.2006.01875.x","article-title":"Quantification of S100A12 (EN-RAGE) in Blood Varies with Sampling Method, Calcium and Heparin","volume":"65","author":"A Larsen","year":"2007","journal-title":"Scandinavian Journal of Immunology"},{"key":"pone.0282841.ref009","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/bs.acc.2018.07.005","article-title":"Fecal Calprotectin","volume":"87","author":"RM Ayling","year":"2018","journal-title":"Advances in clinical chemistry"},{"issue":"26","key":"pone.0282841.ref010","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1021\/jacs.7b01212","article-title":"Nickel Sequestration by the Host-Defense Protein Human Calprotectin","volume":"139","author":"TG Nakashige","year":"2017","journal-title":"Journal of the American Chemical Society"},{"issue":"2","key":"pone.0282841.ref011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.chom.2011.07.004","article-title":"Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of Staphylococcus aureus","volume":"10","author":"TE Kehl-Fie","year":"2011","journal-title":"Cell host & microbe"},{"issue":"10","key":"pone.0282841.ref012","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-018-1173-4","article-title":"Calprotectin (S100A8\/S100A9): a key protein between inflammation and cancer","volume":"67","author":"F Shabani","year":"2018","journal-title":"Inflammation Research"},{"issue":"3","key":"pone.0282841.ref013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vetimm.2013.07.002","article-title":"Recombinant bovine S100A8 and A9 enhance IL-1\u03b2 secretion of interferon-gamma primed monocytes","volume":"155","author":"M Koy","year":"2013","journal-title":"Veterinary immunology and immunopathology"},{"issue":"12","key":"pone.0282841.ref014","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.str.2016.09.011","article-title":"The Structure of the RAGE:S100A6 Complex Reveals a Unique Mode of Homodimerization for S100 Proteins","volume":"24","author":"L Yatime","year":"2016","journal-title":"Structure (London, England: 1993)"},{"issue":"3","key":"pone.0282841.ref015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.1008647","article-title":"The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer","volume":"86","author":"JM Ehrchen","year":"2009","journal-title":"Journal of leukocyte biology"},{"key":"pone.0282841.ref016","doi-asserted-by":"crossref","first-page":"32804","DOI":"10.1038\/srep32804","article-title":"CD147\/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis","volume":"6","author":"X Xin","year":"2016","journal-title":"Scientific reports"},{"key":"pone.0282841.ref017","doi-asserted-by":"crossref","first-page":"178614","DOI":"10.1155\/2010\/178614","article-title":"S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling, sarcomeric, and mitochondrial function","volume":"2010","author":"M V\u00f6lkers","year":"2010","journal-title":"Journal of biomedicine & biotechnology"},{"issue":"6","key":"pone.0282841.ref018","first-page":"2499","article-title":"Circulating calprotectin as a biomarker of laryngeal carcinoma","volume":"274","author":"MF Topuz","year":"2017","journal-title":"European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology\u2014Head and Neck Surgery"},{"issue":"11","key":"pone.0282841.ref019","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/ncb1794","article-title":"The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase","volume":"10","author":"S Hiratsuka","year":"2008","journal-title":"Nature cell biology"},{"issue":"2","key":"pone.0282841.ref020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbamcr.2007.10.015","article-title":"S100A8\/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac\/DIABLO and Omi\/HtrA2","volume":"1783","author":"S Ghavami","year":"2008","journal-title":"Biochimica et biophysica acta"},{"issue":"5","key":"pone.0282841.ref021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10408363.2019.1619159","article-title":"Clinical value of fecal calprotectin","volume":"56","author":"A Ricciuto","year":"2019","journal-title":"Critical reviews in clinical laboratory sciences"},{"issue":"11","key":"pone.0282841.ref022","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/ibd.22863","article-title":"Fecal Calprotectin Concentration Predicts Outcome in Inflammatory Bowel Disease After Induction Therapy with TNF\u03b1 Blocking Agents","volume":"18","author":"P Molander","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8","key":"pone.0282841.ref023","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/ecco-jcc\/jjz023","article-title":"Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases","volume":"13","author":"A Buisson","year":"2019","journal-title":"Journal of Crohn\u2019s & colitis"},{"issue":"33","key":"pone.0282841.ref024","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","article-title":"From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting","volume":"24","author":"MG Mumolo","year":"2018","journal-title":"World J Gastroenterol"},{"key":"pone.0282841.ref025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cca.2020.08.025","article-title":"Calprotectin in inflammatory bowel disease","volume":"510","author":"F Khaki-Khatibi","year":"2020","journal-title":"Clinica Chimica Acta"},{"issue":"3","key":"pone.0282841.ref026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/gut.49.3.402","article-title":"Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma","volume":"49","author":"J Tibble","year":"2001","journal-title":"Gut"},{"issue":"17","key":"pone.0282841.ref027","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.3748\/wjg.v20.i17.4994","article-title":"Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma","volume":"20","author":"FS Lehmann","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"pone.0282841.ref028","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/0004563215578191","article-title":"Faecal calprotectin as a marker for oesophago-gastric cancer","volume":"52","author":"Z Vincent","year":"2015","journal-title":"Annals of Clinical Biochemistry"},{"issue":"8","key":"pone.0282841.ref029","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1530\/EC-21-0138","article-title":"Lean mass, magnesium, faecal calprotectin and glucocorticoid exposure as risk factors for low bone mineral density in inflammatory bowel disease patients","volume":"10","author":"I Soare","year":"2021","journal-title":"Endocrine connections"},{"issue":"7","key":"pone.0282841.ref030","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1111\/apa.15856","article-title":"Faecal calprotectin in children with multisystem inflammatory syndrome: A pilot case-control study","volume":"110","author":"D Gonzalez Jimenez","year":"2021","journal-title":"Acta paediatrica (Oslo, Norway: 1992)"},{"issue":"9","key":"pone.0282841.ref031","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/rheumatology\/kez098","article-title":"Calprotectin discriminates septic arthritis from pseudogout and rheumatoid arthritis","volume":"58","author":"A Baillet","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"issue":"8","key":"pone.0282841.ref032","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s10067-018-4091-5","article-title":"Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein","volume":"37","author":"J Hurnakova","year":"2018","journal-title":"Clinical rheumatology"},{"issue":"3","key":"pone.0282841.ref033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.33549\/physiolres.930448","article-title":"Calprotectin\u2014a pleiotropic molecule in acute and chronic inflammation","volume":"53","author":"I Str\u00edz","year":"2004","journal-title":"Physiological research"},{"issue":"11","key":"pone.0282841.ref034","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41409-019-0581-6","article-title":"Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant","volume":"54","author":"P Vijayvargiya","year":"2019","journal-title":"Bone Marrow Transplantation"},{"key":"pone.0282841.ref035","doi-asserted-by":"crossref","first-page":"102344","DOI":"10.1016\/j.bcmd.2019.102344","article-title":"Serum calprotectin: A circulating biomarker of the inflammatory state in Philadelphia-negative myeloproliferative neoplasms","volume":"79","author":"I Kre\u010dak","year":"2019","journal-title":"Blood cells, molecules & diseases"},{"issue":"8","key":"pone.0282841.ref036","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00262-017-1992-0","article-title":"Bone marrow myeloid cells in regulation of multiple myeloma progression","volume":"66","author":"SE Herlihy","year":"2017","journal-title":"Cancer immunology, immunotherapy: CII"},{"issue":"6","key":"pone.0282841.ref037","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"J Bohnhorst","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"pone.0282841.ref038","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/sj.leu.2404229","article-title":"Inflammation and multiple myeloma: the Toll connection","volume":"20","author":"A Mantovani","year":"2006","journal-title":"Leukemia"},{"issue":"14","key":"pone.0282841.ref039","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143433","article-title":"The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer","volume":"13","author":"D Ribatti","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"pone.0282841.ref040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093084","article-title":"MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance","volume":"21","author":"V Desantis","year":"2020","journal-title":"International journal of molecular sciences"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0282841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T17:48:35Z","timestamp":1678988915000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0282841"}},"subtitle":[],"editor":[{"given":"Antonio","family":"Solimando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0282841","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}